AU2023207825A1 - Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine - Google Patents

Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine Download PDF

Info

Publication number
AU2023207825A1
AU2023207825A1 AU2023207825A AU2023207825A AU2023207825A1 AU 2023207825 A1 AU2023207825 A1 AU 2023207825A1 AU 2023207825 A AU2023207825 A AU 2023207825A AU 2023207825 A AU2023207825 A AU 2023207825A AU 2023207825 A1 AU2023207825 A1 AU 2023207825A1
Authority
AU
Australia
Prior art keywords
cov
protein
sars
amino acid
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023207825A
Other languages
English (en)
Other versions
AU2023207825A9 (en
Inventor
Maryline BOURGINE
Pierre Charneau
Ingrid FERT
Jodie LOPEZ
Laleh Majlessi
Benjamin VESIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravectys SA
Original Assignee
Theravectys SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravectys SA filed Critical Theravectys SA
Publication of AU2023207825A1 publication Critical patent/AU2023207825A1/en
Publication of AU2023207825A9 publication Critical patent/AU2023207825A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023207825A 2022-01-17 2023-01-17 Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine Pending AU2023207825A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/IB2022/000035 2022-01-17
PCT/IB2022/000035 WO2023135439A1 (en) 2022-01-17 2022-01-17 Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
PCT/EP2023/051025 WO2023135333A1 (en) 2022-01-17 2023-01-17 Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine

Publications (2)

Publication Number Publication Date
AU2023207825A1 true AU2023207825A1 (en) 2024-08-08
AU2023207825A9 AU2023207825A9 (en) 2024-08-15

Family

ID=80787107

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023207825A Pending AU2023207825A1 (en) 2022-01-17 2023-01-17 Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine

Country Status (9)

Country Link
US (1) US20250090655A1 (https=)
EP (1) EP4466015A1 (https=)
JP (1) JP2025504431A (https=)
KR (1) KR20240135619A (https=)
CN (1) CN118829444A (https=)
AU (1) AU2023207825A1 (https=)
CA (1) CA3242669A1 (https=)
TW (1) TW202337492A (https=)
WO (2) WO2023135439A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
WO2024050483A1 (en) * 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517286A (ja) * 2020-03-13 2023-04-25 オックスフォード ユニヴァーシティ イノヴェーション リミテッド 免疫応答を誘導するための組成物及び方法
CN117120085A (zh) * 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
CA3185952A1 (en) * 2020-07-15 2022-01-20 Pierre Charneau Sars-cov-2 immunogenic compositions, vaccines, and methods
WO2022167831A1 (en) * 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods

Also Published As

Publication number Publication date
KR20240135619A (ko) 2024-09-11
EP4466015A1 (en) 2024-11-27
CN118829444A (zh) 2024-10-22
WO2023135439A1 (en) 2023-07-20
US20250090655A1 (en) 2025-03-20
AU2023207825A9 (en) 2024-08-15
JP2025504431A (ja) 2025-02-12
CA3242669A1 (en) 2023-07-20
TW202337492A (zh) 2023-10-01
WO2023135333A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
US20230023093A1 (en) Dna antibody constructs and method of using same
US20230330215A1 (en) Sars-cov-2 vaccines
US20220112273A1 (en) DNA Antibody Constructs And Method Of Using Same
CA2311647C (en) Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
US20230021583A1 (en) Measles-vectored covid-19 immunogenic compositions and vaccines
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
US20230256084A1 (en) Sars-cov-2 immunogenic compositions, vaccines, and methods
Yao et al. Virus-like particle and DNA-based candidate AIDS vaccines
AU2021226567A1 (en) Vaccines against coronavirus and methods of use
JP2023526073A (ja) 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン
US20250090655A1 (en) Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
JP2021013384A (ja) 最適化ＨＩＶ遺伝子を含有及び発現する遺伝的に安定な複製可能センダイ（Ｓｅｎｄａｉ）ウイルスベクター
Tohidi et al. Induction of a robust humoral response using HIV-1 VLPMPER-V3 as a novel candidate vaccine in BALB/C mice
Moriya et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies
CN117730150A (zh) 用于诱导对SARS-CoV-2的特异性免疫的冻干形式的药剂（变体）
WO2022167831A1 (en) Sars-cov-2 immunogenic compositions, vaccines, and methods
EP4333887A1 (en) Vaccines against coronavirus and methods of use
Center et al. Utility of the Sindbis replicon system as an Env-targeted HIV vaccine
US20130337009A1 (en) Chimeric dna vaccine compositions and methods of use
US20250325657A1 (en) Modified vaccinia ankara (mva) vaccine
US20230233666A1 (en) SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES
Edwards Immunogenicity and protection mediated by next-generation EBV gH/gL vaccines in non-human primate and humanized mouse models of infection
CN117479953A (zh) 针对冠状病毒的疫苗及其使用方法
Reed et al. Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine
Tenbusch et al. Immunogenicity of DNA Vaccines Encoding Simian Immunodeficiency Virus

Legal Events

Date Code Title Description
SREP Specification republished